Q4 2025 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2026-02-13 · accession 0001104659-26-014463
$865.2M
Reported value
8
Positions
2025-12-31
Period end
The Brief · Atlas Venture Life Science Advisors, LLC · Q4 2025
AI · grounded in 13F
Atlas Venture Life Science Advisors, LLC closed its position in Generation Bio, Co. GBIOGBX, reducing its holdings by $5.07M. The fund also exited its position in ImageneBio, Inc. IMA, selling $3.08M. To offset these exits, the fund established a new position in Generation Bio, Co. valued at $4.7M and reduced its stake in Disc Medicine, Inc. IRON by 29.34%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $362.6M | 41.9% | 4,659,874 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $178.6M | 20.6% | 9,130,465 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics, Inc. | $123.2M | 14.2% | 2,995,602 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $120.2M | 13.9% | 1,513,875 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $59.8M | 6.91% | 6,412,560 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $9.1M | 1.05% | 1,137,149 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $6.9M | 0.80% | 2,092,106 | Common | SOLE |
| 37148K209 | — | Generation Bio, Co. | $4.7M | 0.54% | 827,946 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.